ReviewBioMed research international2015
Antibacterial Discovery and Development: From Gene to Product and Back.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 49 citations in OpenAlex.
- Anticancer compounds from Streptomyces: insights from metagenomics and mechanistic perspective.Folia microbiologica · 2025Review
- Strength in diversity: unlocking the full potential of engineered living materials with multistrain collaboration.FEMS microbiology reviews · 2025Review
- Article
- Therapeutic applications and biological activities of bacterial bioactive extracts.Archives of microbiology · 2021Review
- The global preclinical antibacterial pipeline.Nature reviews. Microbiology · 2020Review
- Structure-based Druggability Assessment of Anti-virulence Targets from Pseudomonas aeruginosa.Current protein & peptide science · 2019Review
- Gut microbiota as a source of novel antimicrobials.Gut microbes · 2019Review
- Magnetic Nanoconjugated Teicoplanin: A Novel Tool for Bacterial Infection Site Targeting.Frontiers in microbiology · 2018Article
- Selenazolinium Salts as "Small Molecule Catalysts" with High Potency against ESKAPE Bacterial Pathogens.Molecules (Basel, Switzerland) · 2017Article
- Insights into microbial cryptic gene activation and strain improvement: principle, application and technical aspects.The Journal of antibiotics · 2017Review
- Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Screening for antioxidant and antibacterial activities of phenolics from Golden Delicious apple pomace.Chemistry Central journal · 2016Article
- A Novel Microbisporicin Producer Identified by Early Dereplication during Lantibiotic Screening.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concern over the reports of antibiotic-resistant bacterial infections in hospitals and in the community has been publicized in the media, accompanied by comments on the risk that we may soon run out of antibiotics as a way to control infectious disease. Infections caused by Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and other Enterobacteriaceae species represent a major public health burden. Despite the pharmaceutical sector's lack of interest in the topic in the last decade, microbial natural products continue to represent one of the most interesting sources for discovering and developing novel antibacterials. Research in microbial natural product screening and development is currently benefiting from progress that has been made in other related fields (microbial ecology, analytical chemistry, genomics, molecular biology, and synthetic biology). In this paper, we review how novel and classical approaches can be integrated in the current processes for microbial product screening, fermentation, and strain improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.